The combination therapy of DNMTi and histone deacetylase inhibitors (HDACi) synergistically increases reexpression of silenced ERVs in cancer cells and increases sensitivity to the anti-programmed cell death 1 (PD-1) therapy in lung [26] and ovarian cancers [25]. This evidence concerns the gene PDCD1 and cancer.